Medlab Asia & Asia Health’s Post

I am so excited to have this opportunity to talk about the importance of bioethics as we consider clinical trials supporting the development of AI driven technologies. The foundational principles of bioethics provide a critical starting point for our analysis. Looking forward to engaging with my fellow panelists on this important topic. #bioethics

Our HVL x Taiwan webinar is uploaded here!! Special thanks to Cortilia L., National Taiwan University and TMU BioMed Accelerator for help with co-hosting and organizing Would like to acknowledge our speakers Cortilia L. of Kyalio - Prefers multi-market entry strategy. Taiwan and Singapore primary to specialist referral process different as well as the investor appetite - SG has more risk appetite for proof of concept but the business case must be sound Dr. Nolnabhas Yaemsaard of patRangsit Hospital Group and Alyssa Global Thailand's robust medical tourism, wide UHC coverage and the rise of NCD and aging population makes it a good opportunity for specialty service providers Lucas Fortier of POC Pharma Different purchase drivers at patient to pharmacist to Rx level can be analyzed at the country as well as brand/category of the drugs And our special guest, former Secretary of Health of the Philippines, Dr Manuel Dayrit In the Philippines, tertiary care is more developed than the primary facilities, and private sector comprises 60-70% of all healthcare expenditure. Public sector is more complex compared to private, need to deal with Philhealth. Implications for JV is 1) engagement with govt thru outsourcing or JV, 2) engagement with private sector through partnerships to market and use in the country. New tech, easier to bring as a part of a larger existing solution than a standalone. Recording of the event is here: https://lnkd.in/gwEBWfNy #ASEAN, #publicprivate, #marketentry

APAC has emerged as one of the most promising and resilient markets for clinical trials, outstripping growth in other major regions. This article just posted in BioSpectrum Asia looks at the thriving clinical research landscape in the region and the trends driving its growth. #ClinicalTrials #APAC #ResearchGrowth #Advarra https://lnkd.in/gG_W4ve8

🌏APAC Clinical Trials Growth📈🪴 The Asia-Pacific region is experiencing significant growth in clinical trials, with a 10% increase from 2017 to 2022, outpacing other major regions. Early-Stage Trials Surge: APAC has seen a dramatic rise in early-stage clinical trials, with a growth rate 12 times higher than the US and four times higher than Europe. China's Clinical Research: China leads APAC in clinical trials, primarily conducting domestically sponsored trials, while other countries like 🇯🇵Japan, 🇰🇷South Korea, and India🇮🇳 have a mix of domestic and foreign-sponsored trials. Unlike its counterparts, China predominantly conducts domestically sponsored trials, with over three-quarters of trials being initiated by local companies. In contrast, Japan, South Korea, and India see between 56 and 67 per cent of trials initiated by foreign sponsors. Australia🇦🇺 presents a stark difference, with 95 per cent of trials being initiated by foreign companies. Australia also leads the APAC region in the number of first-in-human (FIH) trials, constituting 7 per cent of its total, according to a recent report from Citeline. South Korea and Taiwan🇹🇼 have also consistently produced good quality biotechs with regional and global ambitions. As a result, you see rapid growth of early phase trials in APAC. “Indonesia🇮🇩, Malaysia🇲🇾, and other countries that have large populations and historically have had less exposure to clinical research are looking to improve their capabilities and attractiveness to the life sciences industry. More mature markets, such as South Korea and Australia, continue to attract clinical research through their cutting-edge healthcare facilities, domain expertise, and overall regulatory attractiveness,” said Bryan C. Spielman, Chief Growth Officer at Advarra. US-based 🅰️dvarra is the market leader in regulatory review solutions and clinical research technology for sites and sponsors. 🧬💨 NSW Health Indian Institute of Science (IISc) Indian Institute of Technology, Kanpur SRM Medical College Hospital and Research Centre SRM University AIIMS (All India Institute of Medical Sciences, New Delhi) Medanta

Unlike in developed countries where RWD is well commercialized (well, sort of), RWD business in emerging markets is hard to grow. One solution is to create a special zone for RWD, with specialized policies to stimulate its growth. Hainan is such a magical island of RWD/E in China; Telangana may be an RWE heaven in India. But can this model, created by government, survive and flourish in free market? In 2024 Chinese Medical Affairs Conference, a group of RWD/E scientists discussed this question. From left, Prof Yang Yu, West China Hospital; Dr. Li Xie, Head of RWE, Happy Life Tech; Dr. Sha Tao, Head of RWE China, Roche; myself; Dr. Yue Wang, Head of Digital Med, AZ China; Lisa Sun, General Manager, TigerMed; Dr. Tony Guo, VP IQVIA. What did we learn during the 2 hour discussion? With strong support from government, it’s easy to survive. But to flourish, they need to go out of the comfort zone and open its mind for collaboration.

RESEARCH DOWN UNDER ▸ Over 32,000 clinical trials have been conducted down under in the past 25 years, showcasing Australia's critical role in global health innovation. 🔬 🌏 Increasingly recognised for its contributions to clinical research, Australia leverages strong regulatory frameworks, world-class research infrastructure, and diverse patient population to drive improvements in health innovation. 👩⚕️ Clinical research also contributes more than a billion dollars to the local economy each year and employs over 8,000 medical and research professionals. In support of the continued growth and innovation of the sector, Akesa is exhibiting at Society for Clinical Research Sites (SCRS)'s Australia & New Zealand Site Solutions Summit in Melbourne next week where industry experts will come together to discuss the latest trends and insights impacting research sites. 👋 Visit our booth to connect and share insights, and discover how Akesa can support your site needs. #Akesa #ANZSiteSolutionsSummit #BioTech #MedTech #HealthInnovation #ClinicalTrials #Networking 🌟

It’s never too early to ... Save the Date! ROHEALTH Cluster in partnership with the Babes-Bolyai University, Suport Center Region Association, Romanian Society of Medical Informatics and Transilvania IT Cluster – are launching the BeHealth event! 👉🏻 BeHealth & Digital 2024 – International Event in Healthcare 📅 22-25 October / Romania ⌚ Exact time TBA and location in Cluj! The 7th edition of this event will provide the perfect environment for international partnerships, resulting in increased economic competitiveness in health and bioeconomy-related. Tailored for companies, hospitals, home care organizations, pharma, and health innovation companies, the event will: 👉 Facilitate discussions on leveraging bioeconomy and digital solutions to address pressing healthcare challenges in Romania and beyond 👉 Provide a platform for meaningful collaborations between companies, organizations, universities and public entities, fostering synergies to effectively meet healthcare needs 👉 Opportunity to present your best business idea in the International Start-ups in Healthcare Competition, participate in the Abstracts Contest, and showcase your creativity and skills in the Digital Challenge Contest Stay tuned for updates as we unveil the full agenda and speaker lineup for this event driving innovation in healthcare and digital transformation! #staytuned #BEHEALTH #Digital #International #Event #Healthcare #RoHealth #Health #Bioeconomy #Digital #Contests #BeThere

Planning to attend DIA-San Diego? Let's schedule a time to meet and explore potential synergies for Japan and Asian Market. Together, we can make clinical trials more accessible, efficient, and patient-friendly in Japan. ⛩⛩ #DIA2024 #ClinicalTrialsInnovation #PatientFirst #HomeBasedTrials #HealthcareCollaborationInJapan #RemoteTrialinJapan #ClinicalTrialinAsia

A significant milestone for T&CM in Malaysia! As one of the 179 WHO member states, Malaysia is taking a leading role in setting research policies to gather evidence that will advance Traditional & Complementary Medicine (T&CM) towards achieving Universal Health Coverage (UHC) and establish a clear direction for T&CM research in the country. It was a privilege to be part of the Research Priorities for T&CM in Malaysia workshop recently, where key areas such as therapeutic claims for traditional herbal products, economic evaluation of T&CM practices, and healthcare financing were highlighted. The identified priority domains—Practice Evaluation, Product Development, Innovation and Education Needs —mark a significant step forward. Collaboration between T&CM and allopathy is essential for building strong scientific evidence and advancing integrated healthcare. It’s inspiring to see Malaysia’s leadership in shaping the future of evidence-based Traditional & Complementary Medicine research, with active engagement from diverse stakeholders. Kudos 🎈T&CM Division, MOH Malaysia

🤔As #communicators, awareness days are a constant struggle: do we communicate or not on that day? Despite holding significant importance, it can sometimes feel like a traffic jam, where crucial messages get lost in the noise. This is unfortunate because the intent behind these days is noble—raising awareness and sparking conversations that matter. 💪As May draws to a close, I wanted to praise #ClinicalTrialsInternationalDay as I am proud to be part of a company that is a frontrunner in investing in clinical trials, driving innovation to reach patients who need it most. 👉 However deciding to participate in such a study is a complicated and deeply personal decision for patients. That is why at Roche Belgium & Luxembourg we asked our colleagues who face the challenge of finding patients every day for our trials to demystify some of the most common myths. 🐹Who has never thought about it for instance: are clinical trial participants just guinea pigs? Check out this video where our colleague Wim Huygens, Senior Clinical Operations Lead, debunks this myth. Discover all available trials in Belgium on the www.clinicaltrial.be platform.